FDA Approves Edluar
Orexo's Edluar (formerly Sublinox) receives FDA approval for the treatment of insomnia
UPPSALA, Sweden, March 16, 2009--Orexo today announces that the US Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Orexo's partner Meda acquired the exclusive worldwide commercialization license for Edluar last year and they expect to launch the product in the US market during the 2nd half of 2009. Orexo will receive royalties on Meda's sales of Edluar.
This approval triggers a milestone payment to Orexo from Meda. The amount of the milestone is USD 5 million and is based upon the product labelling.
Commenting on the news Torbjörn Bjerke, CEO of Orexo, said "I am delighted that the FDA has approved Edluar for the treatment of short-term insomnia. This is a great achievement by Orexo. Edluar provides a convenient sublingual administration and we believe that this offers insomnia sufferers an effective alternative. This is the second product approved in a major market within 12 months and is an excellent achievement. The milestone payment and the anticipated product launch during 2nd half of 2009 will continue Orexo's progress towards profitability."
About Edluar
Edluar (formerly known as Sublinox) is a fast-acting, sublingual formulation of the well-known substance zolpidem and has been approved for the temporary treatment of insomnia. It is based on Orexo's sublingual technology, involving a tablet placed under the tongue for fast and effective absorption of the active substance across the oral mucosa.
About Insomnia
Insomnia is the disturbance of a normal sleep pattern, characterized by the inability to fall asleep, or to stay asleep long enough to get a proper night's sleep. It is thought to affect 1 in 4 adults at some point during their lives. According to the U.S. Department of Health and Human Services, approximately 64 million Americans suffer from insomnia on a regular basis each year. Insomnia occurs 1.4 times more commonly in women than in men.
Insomnia can last for days, months or years and can be split into three categories:
- Transient insomnia, which lasts for 2-3 days
- Short-term insomnia, which lasts for more than a few days, but less than three weeks
- Chronic insomnia, which can be defined as insomnia most nights for three weeks or longer
About Orexo
Orexo is a pharmaceutical company focused on developing drugs for the treatment of pain and inflammation. The company has three products on the market as well as a competitive product portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 128 employees, and has its head office located in Uppsala, Sweden.
For more information, please contact: Torbjörn Bjerke, President and CEO, Orexo Tel: +46 (0)708-66 19 90 E-mail: torbjorn.bjerke@orexo.com
Johan Andersson, Investor Relations Manager, Orexo Tel: +46 (o) 702-10 04 51 E-mail: johan.andersson@orexo.com
Posted: March 2009
Related articles
- Meda: The FDA has accepted for filing the registration application for Sublinox - July 29, 2008
- Orexo Has Submitted the Registration Application for Sublinox (OX22) to the FDA - May 15, 2008
Edluar (zolpidem) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
